Agios Pharmaceuticals (AGIO)

• Market cap: $1.9B
• 1 day: -0.34%
• 5 days: 0.51%
• 1 month: -8.14%
• 3 months: -25.66%
• 6 months: -3.37%
• Year to date: 17.03%
• 1 year: -25.03%
• 5 years: -28.21%
• 10 years: -42.18%
• Sector: Healthcare
• Industry: Biotechnology

About: Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Employees: 540